Danaher Corporation (DHR) FY2025 10-K and Q3 FY2026 10-Q Summary

Business

Source: Annual Report on Form 10-K for the fiscal year ended December 31, 2025, accession 0000313616-26-000062; segment detail for 2026 from the Form 10-Q for the quarter ended September 25, 2026, accession 0000313616-26-000199.

Danaher sells instruments, consumables, software and services to the companies and institutions that discover, make and test medicines and that diagnose disease: biopharmaceutical manufacturers and contract manufacturers, life-science researchers in academia and industry, and hospitals, reference laboratories and physicians' offices. Most of its revenue is recurring. In 2025, $20.1 billion of its $24.6 billion of sales came from consumables, services and operating-type leases that customers buy repeatedly, and $4.4 billion from equipment sales. It sells mainly through its own direct sales force, runs more than 15 operating companies organized into three segments, and has facilities in about 50 countries. About 59% of 2025 sales came from customers outside the U.S. and about 11% from China. High-growth markets made up about 29% of sales. At the end of 2025 the company had about 60,000 employees.

The operating companies share a management method, the Danaher Business System (DBS), a set of continuous-improvement tools organized around growth, lean, leadership and fundamentals. Danaher grows partly by acquiring businesses and regularly reshapes its portfolio. It separated Fortive in 2016, Envista in 2019 and Veralto in 2023 through spin-offs, a split-off and an initial public offering, and in 2026 it bought the patient-monitoring company Masimo.

The three segments, with 2025 sales and operating margins:

• Biotechnology ($7.29 billion of sales; 25.6% operating margin). Its main business is bioprocessing: cell-culture media, chromatography resins, filtration, single-use hardware and consumables, and full manufacturing suites used to develop and produce biologic drugs such as monoclonal antibodies, vaccines, insulin and cell, gene and nucleic-acid therapies. The segment also includes a discovery and medical business (lab filtration, protein purification and analytics, and healthcare filtration). Key brands are CYTIVA and PALL. Recurring revenue was $6.42 billion of the segment's $7.29 billion.
• Life Sciences ($7.33 billion; 7.1% operating margin). Instruments include flow cytometry and lab automation, mass spectrometry and microscopy. Consumables include custom DNA/RNA oligonucleotides, plasmid DNA and mRNA, and antibodies and assays. Key brands include ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX. The segment also has an industrial filtration, separation and purification business serving microelectronics, aerospace, energy and food and beverage customers. It is the segment most exposed to equipment demand: $2.49 billion of its sales were nonrecurring.
• Diagnostics ($9.94 billion; 26.7% operating margin). Molecular diagnostics covers respiratory, healthcare-associated infection, sexual health and virology testing. Clinical diagnostics comprises the clinical lab, acute care (blood gases, electrolytes, cardiac markers, anemia and glucose testing) and anatomical pathology businesses. Key brands include BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMOTOME and RADIOMETER. Masimo, acquired June 10, 2026, has been part of this segment since then. In the third quarter of 2026 Diagnostics was the largest segment, with $2.88 billion of the $6.55 billion total.

According to the company, no competitor offers all of its product lines. It competes on quality, performance, service networks, innovation and price, and faces growing competition from well-funded entrants, low-cost manufacturers and specialized early-stage companies.

Risk factors

Source: Form 10-K for fiscal 2025, accession 0000313616-26-000062, Item 1A; one risk factor added in the Q3 2026 Form 10-Q, accession 0000313616-26-000199, Part II Item 1A.

The risks that matter most for this business:

• Biotech funding and demand cycles. Lower funding for biotechnology companies, especially smaller ones, has reduced demand for some products. Some businesses have been through de-stocking cycles. Equipment demand depends on customers' capital budgets and on interest rates. Funding for government and academic research has been cut by policy changes and agency downsizing.
• Respiratory-testing volatility. Molecular diagnostics demand depends on how severe the flu and COVID-19 seasons are. Customers stocking up ahead of a season can pull demand forward, which can hurt later quarters.
• China and healthcare cost containment. China's volume-based procurement program and reimbursement changes have lowered prices and hurt revenue in Diagnostics. Governments, U.S. reimbursement schemes (PAMA's clinical lab fee schedule, the Inflation Reduction Act) and consolidating hospital purchasing groups are all pushing prices down.
• Tariffs and trade policy. New U.S. tariffs and retaliatory tariffs raise input costs and force surcharges or price increases, which can weaken demand. The Supreme Court ruled in February 2026 that IEEPA does not authorize tariffs, and the administration then imposed new tariffs under other statutes, so the overall effect is still uncertain. China also promotes locally made medical devices.
• Acquisition execution and leverage. Danaher's growth depends partly on buying businesses at sensible prices. Past deals have left about $61.0 billion of goodwill and other intangibles on the balance sheet at December 31, 2025. The company has already recorded impairments, and further ones are possible. Debt rose to fund Masimo, and Danaher's credit facilities cap its consolidated leverage ratio.
• Spin-off tax exposure. If the Fortive, Envista or Veralto separations were found to be taxable, the company and its shareholders could owe significant tax.
• Regulation of medical devices and healthcare practices. FDA 510(k) and PMA clearance, EU MDR/IVDR transition deadlines running from May 2026 to 2028, rules on off-label promotion, anti-kickback and False Claims Act exposure, and staffing cuts at U.S. agencies that could slow product reviews.
• Cybersecurity, data privacy and AI. Connected devices and IT systems can be attacked. GDPR fines can reach 4% of worldwide turnover. Deploying AI brings its own risks to accuracy, intellectual property and reputation.
• Product defects and recalls. Quality problems can lead to recalls, product-liability claims and lost market share.
• Currency and tax. About 59% of sales are outside the U.S., so translation effects are large. Tax audits are open, and global minimum-tax rules (OECD Pillar Two) and U.S. tax legislation could change the company's effective rate.
• Military conflict (added in Q3 2026). In 2026 military conflict spread across several Middle Eastern countries. It disrupted energy supplies and supply chains, raised energy and supply costs and made capital markets volatile. Danaher saw delivery delays and higher logistics costs for customers in the region but no material disruption to its own operations through the first nine months of 2026.

Management's discussion, fiscal 2025

Source: Form 10-K for fiscal 2025, accession 0000313616-26-000062, Item 7.

Sales grew 3.0% in 2025 to $24.57 billion. Core sales, which exclude acquisitions and currency, grew 2.0%, and a weaker dollar added 1.0 point. Bioprocessing drove the year. Biotechnology core sales rose 6.5%, led by high-single-digit growth in bioprocessing consumables bought by large pharmaceutical companies and contract manufacturers, partly offset by lower equipment sales. Life Sciences core sales fell 1.5%. Two large customers bought fewer plasmids and less mRNA, emerging-biotech and academic customers had less funding, and microscopy declined, which outweighed growth in filtration, flow cytometry and mass spectrometry. Diagnostics core sales rose 1.5%. Pathology, clinical lab sales outside China and acute care offset lower respiratory testing and pricing pressure in China. Price changes added 0.5 point to total sales: plus 2.0% in Biotechnology and minus 1.0% in Diagnostics. Core sales in China declined at a mid-single-digit rate.

Operating margin fell from 20.4% to 19.1%. Most of the drop came from intangible-asset and facility impairments, worth 120 basis points net of 2024's charges. These included a $432 million pretax write-down of a genomics-consumables trade name, recorded after Life Sciences was reorganized in mid-2025. Life Sciences margin fell to 7.1% from 12.0%. Net earnings from continuing operations were about $3.6 billion, or $5.03 per diluted share, compared with $3.9 billion, or $5.29, in 2024. Incremental tariff costs were less than $300 million, and the company says it largely offset them with footprint changes, surcharges and productivity actions. Interest income fell $87 million to $30 million because cash went to share repurchases.

Operating cash flow was about $6.4 billion, down 4%. Capital spending was about $1.2 billion. Total debt was about $18.4 billion and cash about $4.6 billion at year-end. In October 2025 the company raised about CHF 1.2 billion in Swiss franc bonds. Going into 2026, management expected bioprocessing growth similar to 2025, a modest improvement in Life Sciences end markets that would still leave growth below historical rates, and faster Diagnostics growth as the worst of China's policy headwinds passed. It guided to an effective tax rate of about 17.0%. Danish authorities have issued tax assessments of about DKK 2.1 billion (about $326 million), which the company is contesting. The goodwill reporting unit with the least headroom at the annual test had a fair value about 20% above its roughly $10.1 billion carrying value.

Current quarter, Q3 2026

Source: Form 10-Q for the quarter ended September 25, 2026, accession 0000313616-26-000199 (MD&A and Notes 2, 5, 11, 13 and 14); outlook and non-GAAP figures from the earnings release furnished as Exhibit 99.1 to the Form 8-K of October 21, 2026, accession 0000313616-26-000201; earlier 2026 guidance from the earnings releases of April 21, 2026 (accession 0000313616-26-000109) and July 21, 2026 (accession 0000313616-26-000163); Masimo deal expectations from the Form 8-K of February 17, 2026, accession 0001193125-26-053124; leadership changes from the Form 8-K of August 3, 2026, accession 0001193125-26-330652.

Results. Underlying growth picked up, while the Masimo acquisition added revenue and diluted margins. Sales rose 8.3% to $6.55 billion (Danaher, which rounds its growth figures to the nearest half point, reports 8.5%). Acquisitions, mostly Masimo, added 6.5 points, and refunds of IEEPA tariffs passed back to customers subtracted 1.0 point. Core sales grew 3.0%, and 5.5% excluding respiratory testing, with all three segments growing on that basis. Demand from applied, clinical, pharmaceutical, biopharmaceutical and biotech customers strengthened from the prior quarter. Academic and government demand also improved but stayed muted. Prices fell 0.5%. Core sales were flat in developed markets, where a decline in North America (lower respiratory sales) offset mid-single-digit growth in Western Europe. Core sales rose 10% in high-growth markets, led by high-single-digit growth in China, and those markets made up about 31% of sales.

Net earnings from continuing operations were $1.21 billion ($1.71 per diluted share), compared with $908 million ($1.27). Including a $28 million income tax benefit in discontinued operations, from releasing reserves after audit settlements on tax returns filed jointly with Veralto and Fortive entities before their separations (10-Q Note 3, accession 0000313616-26-000199), net earnings were $1.24 billion, or $1.75 per diluted share. Most of the increase came from a $263 million discrete tax benefit ($0.37 per share) from releasing uncertain-tax-position reserves after audit settlements, which put the quarter's effective tax rate at -6.6%. Lower impairment charges than in Q3 2025 also helped. Operating margin was 19.0%, against 19.1% a year earlier. Higher core sales and IEEPA tariff refunds added 170 basis points and the absence of last year's impairments added 85. Against that, the Masimo inventory step-up cost 130 basis points, the dilutive effect of acquired businesses 125 and special equity-award expense 20. Tariff refunds are booked as a reduction of cost of sales. Net of refunds passed to customers, their effect on net earnings was less than $100 million. Adjusted diluted EPS, a non-GAAP measure, was $2.11, up 11.5%. Operating cash flow was $1.89 billion and free cash flow $1.63 billion.

Segments.

• Biotechnology: sales $1.81 billion (+0.5% reported). Core sales rose 5.0% after excluding a 4.0-point reduction from tariff refunds to customers. Bioprocessing core sales grew toward the upper end of mid-single digits on consumables, and equipment sales also improved. Discovery and medical declined. Operating margin rose to 26.4% from 19.6%.
• Life Sciences: sales $1.87 billion (+4.0%), core +4.5%, led by filtration (microelectronics and aerospace) and by flow cytometry/lab automation and mass spectrometry, where pharma demand was strong and U.S. academic spending improved modestly. Operating margin was 13.9%, up from 12.4%, including a 45-basis-point gain from settling an acquisition-related contingency.
• Diagnostics: sales $2.88 billion (+17.0%, of which 16.5 points came from acquisitions). Core sales rose 0.5%, and 7.0% excluding respiratory testing. Clinical lab, pathology and acute care grew, core sales in China grew year over year, and respiratory tests declined because less disease was circulating. Prices fell 1.0%, mainly because of China's procurement program. Operating margin fell to 21.3% from 27.0%: acquired-business dilution cost 365 basis points and the Masimo inventory step-up 295.

Nine months. Sales rose 6.0% to $18.77 billion, with core sales up 2.0% and up 4.5% excluding respiratory testing. Diagnostics core sales fell 0.5% on lower respiratory demand and Chinese pricing. Net earnings from continuing operations were $3.11 billion ($4.38 per diluted share), against $2.42 billion ($3.37). Operating cash flow rose 10% to $4.74 billion.

Masimo acquisition and its financing. Danaher agreed on February 16, 2026 to buy Masimo, a maker of pulse oximetry and patient-monitoring systems with about $1.5 billion of 2025 revenue. It valued the deal at about $9.9 billion including assumed debt and net of acquired cash. The deal closed on June 10, 2026, earlier than the second-half 2026 timing originally expected, at $180.00 per share in cash, about $9.8 billion net of cash acquired. Preliminary purchase accounting records about $4.9 billion of goodwill and $5.0 billion of intangibles: $3.4 billion of developed technology, $895 million of customer relationships and $660 million of trade names. When the deal was announced, Danaher said it expected Masimo to:

• add $0.15–$0.20 to adjusted EPS in the first full year and about $0.70 by the fifth;
• produce more than $125 million of annual cost synergies and more than $50 million of revenue synergies by the fifth full year.

Danaher paid for Masimo with cash, commercial paper and new long-term debt:

• €3.0 billion of euro notes issued April 29, 2026, due 2028–2038, with net proceeds of about $3.5 billion;
• CHF 2.383 billion of Swiss franc notes placed June 3, 2026, due 2031–2056, with net proceeds of about $3.0 billion;
• commercial paper backed by a $5.0 billion 364-day credit facility signed April 16, 2026.

Total debt was $26.5 billion at September 25, 2026, up from $18.4 billion at December 31, 2025, and included $4.7 billion of euro commercial paper. Cash was $5.7 billion. Besides Masimo, the company bought one small Life Sciences business for $37 million in cash plus $79 million of deferred consideration. The Masimo deal also brought pending litigation and investigations, described under Legal matters below.

Capital returns. Danaher bought back no shares in the third quarter. Year-to-date repurchases were about 5.0 million shares for $903 million, and 32 million shares remain under the 2025 program. The quarterly dividend rose to $0.40 per share, payable October 30, 2026; it was $0.32 at the start of the year.

Leadership and compensation. Julie Sawyer Montgomery became President and CEO on October 1, 2026, succeeding Rainer M. Blair. She joined Danaher in 2017, ran Beckman Coulter Diagnostics and then the Diagnostics group, and had been an Executive Vice President since July 2024. On August 4, 2026 the company made special long-term growth awards that vest over periods from 12 months to five years. They included a $20 million target-value option grant to the new CEO and, for each co-founder, Steven and Mitchell Rales, options on 1.0 million shares and RSUs on 0.5 million shares. The awards cost $14 million in the quarter. The company excludes them from adjusted EPS.

Outlook (October 21, 2026).

• Fourth quarter: core revenue growth of about 3.0%, or 4.0%–5.0% excluding respiratory, with respiratory expected to subtract about 150 basis points.
• Full year 2026 core revenue: the outlook table shows growth of about 2.5%. The July outlook had called for 3.0%–4.0%. The October figure uses the new definition that excludes tariff refunds to customers.
• Full year 2026 adjusted diluted EPS: raised to $8.57–$8.62, from $8.45–$8.60 in July and $8.35–$8.55 in April.
• Other full-year assumptions: effective tax rate about 17.0%, amortization of acquired intangibles about $1.9 billion, and currency adding about 1.0% to sales.

Starting with this quarter's report, Danaher excludes tariff refunds passed back to customers from its core sales measures.

Legal matters

Source: Form 10-Q, accession 0000313616-26-000199, Note 13.

• Hawkins securities class action: alleges misstatements about bioprocessing revenue between 2022 and 2023. The court gave final approval to a settlement in September 2026. The company has recorded a settlement liability offset by an insurance receivable and expects no material impact. New shareholder derivative suits making the same allegations were filed beginning in March 2026.
• Masimo v. Apple (patents and trade secrets): a jury awarded Masimo $634 million for patent infringement in November 2025, and final judgment was entered on July 20, 2026. Both sides have appealed.
• ITC exclusion order against Apple Watch: the order remains in effect. Apple has petitioned the Supreme Court. Separately, the ITC found that Apple's redesigned watch does not violate the order, and Masimo has appealed that finding.
• DOJ investigation of Masimo's Rad-G and Rad-97 products: Danaher estimates the reasonably possible loss at about $5 million to $40 million.
• Disputes with Masimo's former CEO Joe Kiani: he claims severance including the value of 2.7 million Masimo shares and a $35 million cash payment. Related matters include a Section 16(b) short-swing-profit suit against RTW, and an arbitration with Willow Laboratories over royalties that has a hearing set for November 2026.

Subsequent events

Source: Form 10-Q for the quarter ended September 25, 2026, accession 0000313616-26-000199 (Note 2, Note 8, Note 11, Note 13 and Note 14); board changes from the Form 8-K filed October 13, 2026, accession 0000313616-26-000193; StatLab announcement from the July 21, 2026 earnings release, accession 0000313616-26-000163.

These events occurred after the quarter ended on September 25, 2026:

• StatLab acquisition (September 28, 2026). Danaher bought StatLab Medical Products, a provider of pre-analytical consumables and equipment for the histology workflow, for about $1.4 billion in cash, including assumed debt and net of acquired cash. It paid with cash on hand. StatLab had about $250 million of revenue in 2025 and will be reported in the Diagnostics segment starting in the fourth quarter of 2026. Leica Biosystems, Danaher's pathology business, had announced the deal in July 2026.
• Debt repayment (September 30, 2026). Danaher repaid the €800 million of 2.1% 2026 Euronotes at maturity from cash on hand. They were carried at $912 million on September 25.
• U.S. pension plan termination (effective September 30, 2026). The board approved terminating the U.S. defined benefit pension plan. The plan's assets had not been distributed as of that date. Obligations are expected to be settled through lump-sum payments and annuity purchases. The company is still assessing potential settlement charges.
• Masimo v. Apple interest award (October 5, 2026). The District Court awarded Masimo about $184 million of pre-judgment interest on top of the $634 million verdict, and post-judgment interest on the combined amount. The case is on appeal.
• Founders waive RSUs (October 9, 2026). Steven and Mitchell Rales each gave up, for no consideration, the 500,000-share restricted stock unit awards granted to them on August 4. Danaher will record the remaining $185 million of unrecognized cost as a non-cash charge in the fourth quarter of 2026.
• Board changes (October 9, 2026). The board grew to 13 members with the appointment of Daniel L. Comas, Danaher's CFO from 2005 to 2018, and Robert M. Hershberg. Alan G. Spoon will retire from the board at the 2027 annual meeting.